Table 3

Base case results of cost-effectiveness analysis (both direct and indirect costs were considered in the analysis)
Direct comparison Total cost QALYs Incremental cost Incremental QALYs ICER
Agomelatine vs. comparator Agomelatine vs. comparator
Agomelatine €5,434 1.461 - - -
Venlafaxine €5,420 1.436 €14 0.026 €547/QALY
Sertraline €5,650 1.427 - €215 0.034 Agom. dominant
Escitalopram €5,462 1.447 - €28 0.015 Agom. dominant
Fluoxetine €5,563 1.431 - €129 0.030 Agom. dominant
Generic Venlafaxine €5,397 1.436 €37 0.026 €1,446/QALY
Generic Sertraline €5,600 1.427 -€166 0.034 Agom. dominant
Generic Escitalopram €5,386 1.447 €48 0.015 €3,303/QALY
Generic Fluoxetine €5,508 1.431 -€74 0.030 Agom. dominant

QALY Quality Adjusted Life Year.

ICER Incremental cost effectiveness ratio.

Maniadakis et al.

Maniadakis et al. BMC Health Services Research 2013 13:173   doi:10.1186/1472-6963-13-173

Open Data